Skip to main content
. 2006 Jul 17;103(30):11160–11165. doi: 10.1073/pnas.0510834103

Fig. 2.

Fig. 2.

Interaction between MageA2 and p53. (A) Immunoprecipitation (IP) of endogenous p53/Mage protein complex in U2OS cells using anti-p53 polyclonal Ab or preimmune IgG. (B) IP in H1299 cells transfected with HA-MageA2 and the indicated p53 deletions. (C) IP assay similar to that in B but using p53 deletions expressing HA-tagged 94–298 (HA-p53DBD) and HA-p53 298–393 (HA-p53CTD). (D) In vitro binding assay using recombinant/purified GST and GST–p53 fusion protein incubated with IVT 35S-labeled HA–MageA2 (IVT MageA2). (E) In vitro binding assay using recombinant/purified GST and GST–MageA2 fusion protein incubated with IVT 35S-labeled domains of p53:p53NTD (1–98), p53DBD (94–298), and p53CTD (298–393) as indicated. ∗, Ig heavy chain; ∗∗, Ig light chain.